Sotera Health Company (SHC) Covered Calls

Sotera Health Company is a leading global provider of mission-critical sterilization, lab testing, and advisory services for the healthcare industry. Operating through its Sterigenics, Nordion, and Nelson Labs businesses, the company ensures the safety of medical devices, pharmaceuticals, and food products. By providing essential end-to-end solutions for the global health supply chain, Sotera Health helps manufacturers comply with rigorous regulatory requirements and protect patients.

You can sell covered calls on Sotera Health Company to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for SHC (prices last updated Fri 4:16 PM ET):

Sotera Health Company (SHC) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
17.49 +0.09 17.14 17.87 1.1M 87 4.9
Covered Calls For Sotera Health Company (SHC)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Mar 20 17.5 0.45 17.42 0.5% 6.3%
Apr 17 17.5 0.70 17.17 1.9% 12.2%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Sotera Health Company (SHC) is a premier provider of essential health-protection services, serving more than 5,800 customers worldwide. Headquartered in Cleveland, Ohio, the company operates an integrated platform that addresses the complex safety needs of the medical device and pharmaceutical sectors. Its business model is built on three core pillars: Sterigenics (outsourced terminal sterilization), Nordion (global supplier of Cobalt-60), and Nelson Labs (microbiological and analytical chemistry testing). These services are technically demanding and strictly regulated, creating high barriers to entry and long-term customer relationships.

The company plays a vital role in the global healthcare infrastructure, as approximately 90% of its revenue is derived from products that are either single-use or high-turnover medical supplies. In early 2026, Sotera Health expanded its capacity at several key sterilization facilities to meet the rising demand for orthopedic and cardiovascular implants. The Nordion segment continues to lead the world in the production of Cobalt-60, a critical radioisotope used in gamma sterilization, ensuring a stable supply chain for the healthcare providers that rely on terminal sterilization to prevent hospital-acquired infections.

Competitive Landscape

The competitive landscape for Sotera Health consists of specialized sterilization firms and global clinical laboratory giants. Primary rivals that are publicly traded on the NYSE or NASDAQ and offer active options markets include STERIS plc and Thermo Fisher Scientific Inc.. These entities compete for large-scale outsourcing contracts from major medical device and pharmaceutical manufacturers.

Other notable competitors in the healthcare services and diagnostics sectors with active options trading include Danaher Corporation and Agilent Technologies, Inc.. While many firms provide broad laboratory services, Sotera Health distinguishes itself through its "end-to-end" approach—combining world-class testing with specialized sterilization expertise. This deep vertical integration, paired with a global network of over 60 facilities, makes it an indispensable partner for companies navigating the increasingly stringent regulatory landscape governed by the FDA and global health authorities.

Strategic Outlook

Strategic innovation is currently focused on the modernization of its ethylene oxide (EO) facilities and the expansion of its E-beam and X-ray sterilization technologies. By early 2026, the company has successfully implemented advanced emission control systems across its U.S. portfolio, exceeding new EPA standards and solidifying its operational resilience. These environmental upgrades are part of a broader "Safeguarding Global Health" initiative aimed at reducing the carbon footprint of its high-volume industrial processes while maintaining the highest levels of sterility assurance.

The outlook involves a push for higher margins through the growth of its Nelson Labs segment, which is benefiting from the increased complexity of biologic drug testing. Management is prioritizing a disciplined capital allocation strategy that balances internal capacity expansions with debt reduction. In February 2026, the company reiterated its focus on achieving high-single-digit revenue growth by leveraging its leadership in the radioisotope market and expanding its service offerings in emerging biotech hubs. By maintaining its status as a critical-path provider, Sotera Health aims to deliver predictable, defensive growth regardless of broader economic cycles.